Navigation Links
Centrix Pharmaceutical Announces Clofera(TM), a Unique Antitussive and Nasal Decongestant for the Temporary Relief of Cough and Nasal Congestion
Date:8/14/2009

BIRMINGHAM, Ala., Aug. 14 /PRNewswire/ -- Centrix Pharmaceutical, Inc., a privately-held specialty pharmaceutical company focused on Pediatrics and Women's Health, announced plans to commercially launch Clofera(TM) for the temporary relief of cough and nasal congestion.

Clofera(TM) is indicated for the temporary relief of cough and nasal congestion due to the common cold, hay fever, or other upper respiratory allergies. Clofera(TM) contains a non-narcotic antitussive, chlophedianol hydrochloride, in addition to nasal decongestant, pseudoephedrine hydrochloride. The product is specifically formulated without dyes, sugar, alcohol or gluten to meet particular consumer needs and address patient sensitivities. Clofera(TM) is expected to release during the beginning of the fourth quarter.

"We are pleased to introduce Clofera to temporarily control the cough reflex, therefore reducing the intensity of coughing with a product that is free of narcotic effects. Clofera provides physicians with another therapeutic option in the management of cough and congestion associated with allergic rhinitis or the common cold. The release of Clofera further compliments our goal to develop and expand the Centrix specialty portfolio," stated John R. (Bob) Booth, President and CEO of Centrix Pharmaceutical.

About Clofera(TM)

Clofera(TM) temporarily controls the cough reflex, temporarily relieves nasal congestion, swollen nasal passages, sinus congestion and pressure. Clofera(TM) should not be used in patients taking monoamine oxidase inhibitors or with known hypersensitivity to any of the components of the product. Patients with a chronic cough, asthma, emphysema, mucus production, heart disease, high blood pressure, thyroid disease, diabetes, or enlarged prostate should consult physician before use. Recommended dosage should not be exceeded. Clofera(TM) contains no dextromethorphan, antihi
'/>"/>

SOURCE Centrix Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CareCentrix Adds to Senior Leadership Team
2. HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
5. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies
6. WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009
7. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
8. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
9. Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry
10. Sun Pharmaceutical to File HSR Application for Taro Tender Offer
11. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... West Africa is starting to spread faster than ever, the World ... the deadly viral infection were reported in just one week. ... with roughly half of those reported in the past three weeks, ... tops 2,600. WHO has estimated that as many as 20,000 ...
(Date:9/18/2014)... It’s been just a few short weeks ... bunion splint to website visitors, but already the response has ... absolutely delighted. It is perfect and I find it sooo ... THANK YOU FOR LISTENING!!!" Another user compared the original ... used to slip to the end of my toe. Now ...
(Date:9/18/2014)... It is that time of year – time ... again, Evensong Spa at Heidel House Resort ... at a special $50 rate Oct. 20 through Nov. 1. ... & Resorts , is the only Wisconsin destination spa participating ... health and wellness by experiencing affordable spa and wellness treatments. ...
(Date:9/18/2014)... supplements of selenium or vitamin E don,t seem ... men, a new study indicates. Previous animal research ... cataracts. To investigate this further, William Christen, from Brigham ... and his colleagues examined data from a randomized, placebo-controlled ... initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
Breaking Medicine News(10 mins):Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4
... By Randy Dotinga HealthDay Reporter , TUESDAY, Sept. ... gel based on the active ingredient of the injectable Botox ... known as crow,s feet -- without the pain of needles. ... toxin, last for about four months, comparable to that produced ...
... HealthDay Reporter , TUESDAY, Sept. 20 (HealthDay News) -- Young adults ... birth much thought, but a new study finds that health problems ... some time. From 18 to 36 years of age, people ... death compared to young adults born at a normal gestational age, ...
... Reporter , TUESDAY, Sept. 20 (HealthDay News) -- Adding ... and teens with obsessive-compulsive disorder, new research shows. ... the Journal of the American Medical Association , ... obsessive-compulsive disorder (OCD). "[If] a child has ...
... against methamphetamine and nicotine have been selected to receive ... The two scientists, Dr. Thomas Kosten, of Baylor ... the University of Connecticut, Storrs, will each receive $500,000 ... according to the National Institute on Drug Abuse (NIDA), ...
... 20 (HealthDay News) -- New research finds that compared to ... diagnosis and boosted the likelihood that high-risk, underserved women who ... But there,s a big catch. Researchers were able to reduce ... -- compared to the usual $3,500 -- thanks to a ...
... of Health (NIH) has awarded nearly $2 million to ... University to develop a new class of therapeutics for ... five-year project focuses on developing biomaterials capable of capturing ... to wound sites to enhance tissue regeneration in adults. ...
Cached Medicine News:Health News:Anti-Wrinkle Gel Might Work Like Botox Without Needles 2Health News:Anti-Wrinkle Gel Might Work Like Botox Without Needles 3Health News:Problems From Preterm Birth May Return in Adulthood 2Health News:Problems From Preterm Birth May Return in Adulthood 3Health News:Adding Psychotherapy to Meds Helps Kids With OCD 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 3
(Date:9/18/2014)... 2014  Spring Bank Pharmaceuticals, Inc., a clinical-stage ... of RNA viruses, today announced a research collaboration ... animal testing of the Company,s lead compound, SB ... Pathogens," against which currently there are no effective ... Bank,s proprietary Small Molecule Nucleic Acid Hybrid ...
(Date:9/18/2014)... 18, 2014 /CNW/ - A new expert panel report, ... , released today by the Council of Canadian ... medicines for children. Each year about half of ... least one prescription drug. Much of this prescribing is ... use), creating potential health risks. Children have ...
(Date:9/18/2014)... , Sept. 18, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced the first presentation ... AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing ... study evaluated collagenase clostridium histolyticum (CCH) for the ... same hand. In addition, the study examined expanded ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 28, 2011 before the open of the U.S. financial markets. ... live audio webcast at 9:00 a.m. Eastern Time on the ... the 2011 first quarter financial results and other business. ...
... LLC, through its website lawsuitssettlementfunding.com announced today ... in need of lawsuit cash advances ... leader; however they are striving to set themselves apart ... that they have ramped up their operations involving Avandia ...
Cached Medicine Technology:ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011 2Legal-Bay LLC Announces Opening of Jones Act Lawsuit Funding Division 2
Substrate Plasma for Factor V Assay by STA© Analyzers. Freeze-dried human plasma, artificially depleted of factor V....
Substrate Plasma for Factor VIII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VIII has been removed by selective immuno-adsorption....
Immuno-turbidimetric Assay of von Willebrand Factor (vWF) Antigen by STA© Analyzers. Microlatex particles coated with rabbit anti-human vWF antibodies....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Medicine Products: